During the Prevail Phase 2 trial for ZMapp, clinical promise was observed with a strong trend toward improved survival, although efficacy metrics were not reached due to patient access as the Ebola outbreak dissipated.
← all excerpts
Reproducibility and flexibility of monoclonal antibody production with <i>Nicotiana benthamiana</i>.
1
—
—